On 13 June 2008, Novartis Vaccines and Diagnostics S.r.l. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Aflunov, for the prophylaxis of H5N1 avian influenza in adults and the elderly.
Therapeutic Indication
### Therapeutic indication Active immunisation against H5N1 subtype of Influenza A virus in individuals 6 months of age and above. Aflunov should be used in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BB02
ATC Item
influenza, inactivated, split virus or surface antigen
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23) | N/A | influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h 5 n 1)-like strain (nibrg-23) |
EMA Name
Aflunov
Medicine Name
Aflunov
Aliases
N/A